THE SCIENCE
Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been studied extensively for its effects on growth-hormone signaling, the GH/IGF-1 axis, and visceral fat. The sections below provide scientific background on its molecular characteristics, biological activity, and clinical research.
MOLECULAR DESIGN
Tesamorelin is composed of all 44 amino acids of human GHRH with the addition of a trans-3-hexenoic acid group attached to the N-terminal tyrosine residue. This modification makes it more resistant to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4) compared to native GHRH, providing it with a longer half-life and greater potency.
GHRH RECEPTOR ACTIVITY
By binding to and activating GHRH receptors in the anterior pituitary gland, Tesamorelin stimulates the synthesis and pulsatile release of endogenous growth hormone. Unlike synthetic GH, which provides a constant elevation, Tesamorelin maintains the physiological feedback loops that regulate GH levels, reducing the risk of excessive GH accumulation.
GROWTH HORMONE & IGF-1
The GH stimulated by Tesamorelin acts on various tissues, particularly the liver, to induce the production of Insulin-like Growth Factor 1 (IGF-1). IGF-1 mediates many of the growth-promoting and metabolic effects of GH. Clinical studies have shown that Tesamorelin significantly increases IGF-1 levels while remaining within the physiological range for healthy adults.
VISCERAL FAT
- Growth hormone is a potent lipolytic agent, meaning it promotes the breakdown of stored fats. Visceral adipose tissue (VAT)—the deep abdominal fat surrounding internal organs—is particularly sensitive to the effects of GH due to a high density of GH receptors. Research has demonstrated that Tesamorelin specifically targets VAT reduction by stimulating lipolysis and inhibiting lipogenesis in these deep fat stores.
- Unlike subcutaneous fat, visceral fat is highly metabolically active and associated with systemic inflammation and insulin resistance. By reducing VAT, Tesamorelin has been shown to improve the metabolic profile in specific patient populations, such as those with HIV-associated lipodystrophy.
VISCERAL FAT VS. BODY WEIGHT
An important distinction in clinical research is that Tesamorelin primarily reduces visceral fat without significantly altering overall body weight. This indicates a change in body composition—a loss of pathogenic fat often accompanied by the maintenance of lean body mass—rather than general weight loss.
CLINICAL RESEARCH
Data from Phase 3 clinical trials demonstrated that patients receiving Tesamorelin experienced an average 15-18% reduction in visceral fat over a initial 26-week period. These studies also noted improvements in lipid profiles, including decreases in triglycerides and non-HDL cholesterol, highlighting the peptide’s broader metabolic impact beyond simple fat reduction.